Anixa Biosciences Inc Stock Price, News & Analysis

Anixa Biosciences (NASDAQ: ANIX) announced that Cleveland Clinic will present final results from the Phase 1 clinical trial of its breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025. The trial evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer, funded by the U.S. Department of Defense.

The presentation, led by Dr. Justin Johnson, Program Manager at Cleveland Clinic and co-inventor of the vaccine technology, will provide the most comprehensive data release to date. The findings will be submitted to both the Department of Defense and FDA to guide Phase 2 planning discussions. The vaccine technology, based on decades of preclinical work by the late Dr. Vincent Tuohy at Cleveland Clinic, shows promising potential for breast cancer prevention and treatment.

Anixa Biosciences (NASDAQ: ANIX) has completed dosing the fourth cohort in its Phase 1 clinical trial for a novel FSHR-targeted CAR-T therapy treating recurrent ovarian cancer. The fourth cohort received 3×10⁶ CAR-positive cells per kilogram, a 30-fold increase from the first cohort, with no dose-limiting toxicities observed.

Several treated patients have surpassed median survival expectations, with one patient from the first cohort remaining alive 28 months post-treatment. The fifth cohort is planned to receive approximately 1×10⁷ cells/kg following a 30-day safety review. The therapy targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced a time change for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place at 10:30 AM ET on September 9, 2025, at the Lotte New York Palace Hotel.

Mike Catelani, President and CFO, will deliver the presentation and be available for one-on-one meetings during the conference, which runs from September 8-10, 2025. Interested parties can access the presentation via webcast.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, at the Lotte New York Palace Hotel in New York City.

Company President and CFO Mike Catelani will deliver a presentation on September 8, 2025, at 4:30 PM ET. The presentation will be available via webcast, and management will be available for one-on-one meetings during the conference.

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology patent. This marks the company's first Chinese patent and will provide protection into the 2040s.

The patent, exclusively licensed from Cleveland Clinic, covers composition of matter protection for Anixa's novel breast cancer treatment and prevention approach. The vaccine targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers.

This expansion is particularly significant as breast cancer has become the most commonly diagnosed cancer among women in China, with hundreds of thousands of new cases annually. The patent complements existing protection in the United States and other key global markets.

Anixa Biosciences (NASDAQ: ANIX) has announced the treatment of the second patient in the fourth cohort of its Phase 1 clinical trial for ovarian cancer CAR-T therapy. The trial, conducted in partnership with Moffitt Cancer Center, is evaluating a novel treatment targeting the follicle-stimulating hormone receptor (FSHR).

Patients in the fourth cohort are receiving 3 million CAR-positive cells per kilogram of body weight, a 30-fold increase from the initial dose. Notably, no dose-limiting toxicities (DLTs) have been observed in this cohort. The study focuses on adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy, aiming to evaluate safety, determine maximum tolerated dose, and monitor clinical activity.

Anixa Biosciences (NASDAQ: ANIX) has secured a new U.S. patent (No. 12,384,826) for its innovative chimeric antigen receptor-T cell (CAR-T) technology, extending protection until 2045. The patent, issued by the USPTO, covers core methods and compositions of Anixa's CAR-T platform, which is specifically designed to tackle solid tumors.

The technology, currently in clinical trials at Moffitt Cancer Center for treating recurrent ovarian cancer, was originally granted to The Wistar Institute and exclusively licensed to Anixa. This patent adds to the company's growing intellectual property portfolio, strengthening its position in developing breakthrough immuno-oncology treatments.

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, will present at the 13th Annual Ovarcoming Cancer Conference on September 18, 2025. Dr. Wenham, who serves as the principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will discuss advancements in ovarian cancer research and therapies.

The conference, held both virtually and in-person at the Briar Club in Houston, Texas, brings together survivors, caregivers, and medical professionals to discuss important developments in ovarian cancer treatment.

Anixa Biosciences (NASDAQ: ANIX) has initiated the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine from Cleveland Clinic to support an upcoming Phase 2 trial. The vaccine, targeting α-lactalbumin protein, has shown promising results in Phase 1, with over 70% of patients demonstrating protocol-defined immune responses.

The vaccine is designed to target α-lactalbumin, a protein normally expressed during lactation but also present in many breast cancers, potentially offering both therapeutic and preventive benefits. Anixa has engaged Advyzom as its regulatory consultant to manage FDA interactions during the IND transfer process.